Trial Profile
A Phase 2, Open Label, Pilot Study to Examine the Use of Rivaroxaban Plus Aspirin vs. Clopidogrel Plus Aspirin for the Prevention of Restenosis After Infrainguinal Percutaneous Transluminal Angioplasty for Critical Limb Ischemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel
- Indications Chronic limb-threatening ischemia; Peripheral arterial disorders; Peripheral artery restenosis
- Focus Adverse reactions
- Acronyms RIVAL-PAD
- 19 Jul 2019 Status changed from active, no longer recruiting to completed.
- 19 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.
- 17 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.